Financial Inducements: Growth in DTC Magazine Advertisements

References

• Aikin, K. J., Sullivan, H. W., O'Donoghue, A. C., & Betts, K. R. (2016). Consumer perceptions of prescription and over-the-counter drug advertisements with promotional offers. Health Marketing Quarterly, 33(4), 291–306. https://doi.org/10.1080/07359683.2016.1238262
   PubMedGoogle Scholar
• Armour, S. (2019 May 24). Trump administration preparing executive order on health-cost disclosure. Wall Street Journal, https://www.wsj.com/articles/trump-administration-preparing-executive-order-on-health-cost-disclosure-11558690320?mod=hp_lead_pos7.
   Google Scholar
• Ball, J. G. (2014). A comparison of functional and emotional benefit messages within direct-to-consumer prescription drug advertising. In American Academy of Advertising Conference Proceedings (pp. 152).
   Google Scholar
• Bell, R. A., Kravitz, R. L., & Wilkes, M. S. (1999). Direct-to-consumer prescription drug advertising and the public. Journal of General Internal Medicine, 14(11), 651–657. https://dx.doi.org/10.1046%2Fj.1525-1497.1999.01049.x https://doi.org/10.1046/j.1525-1497.1999.01049.x
   PubMed Web of Science ®Google Scholar
• Bell, R. A., Kravitz, R. L., & Wilkes, M. S. (2000). Direct-to-consumer prescription drug advertising, 1989–1998. The Journal of Family Practice, 49(4), 329–335.
   PubMed Web of Science ®Google Scholar
• Bhutada, N. S., Cook, C. L., & Perri, M. (2009). Consumers responses to coupons in direct-to-consumer advertising of prescription drugs . Health Marketing Quarterly, 26(4), 333–346. https://doi.org/10.1080/07359680903315902
   PubMedGoogle Scholar
• Cohen, J. (2018, September 24). To include or not include drug prices in DTC ads. Forbes. https://www.forbes.com/sites/joshuacohen/2018/09/24/to-include-or-not-include-drug-prices-in-dtc-ads/#2460b1cf3c65
   Google Scholar
• Costa-Font, J., McGuire, A., & Varol, N. (2015). Regulation effects on the adoption of new medicines. Empirical Economics, 49(3), 1101–1121. https://doi.org/10.1007/s00181-014-0903-x
   Web of Science ®Google Scholar
• Dan, S. M., & Zondag, M. M. (2016). Drivers of alliance terminations: An empirical examination of the bio-pharmaceutical industry. Industrial Marketing Management, 54, 107–115. https://doi.org/10.1016/j.indmarman.2015.06.006
   Web of Science ®Google Scholar
• Davies, R. (2017). Specialty drugs: Four options for managing costs. Benefits Magazine, 54(6), 30–35.
   Google Scholar
• De Dobbelaer, R., Van Leuven, S., & Raeymaeckers, K. (2017). Dirty dancing: Health journalists and the pharmaceutical industry a multi-method study on the impact of pharma PR on magazine health news. Public Relations Review, 43(2), 450–459. https://doi.org/10.1016/j.pubrev.2017.02.002
   Web of Science ®Google Scholar
• Deutschman, M. (2013, June 17). 1 of 4 consumers use pharma savings offers. KantarMedia.com.
   Google Scholar
• Ehrlich, B. (2017, January 11). DTC in perspective: A new year of DTC challenges. dtcperspectives.com.
   Google Scholar
• Eisend, M. (2018). Old meets new: How researchers can use existing knowledge to explain advertising in new media. International Journal of Advertising, 37(5), 665–670. https://doi.org/10.1080/02650487.2018.1493825
   Web of Science ®Google Scholar
• FDA Guidance (2015, August). Brief summary and adequate directions for use: Disclosing risk information in consumer-directed print advertisements and promotional labeling for prescription drugs guidance for industry. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM069984.pdf
   Google Scholar
• Ferber, R., & Wegner, W. O. (1960). Trends in pharmaceutical advertising. Journal of Marketing, 24(4), 65–67. https://doi.org/10.2307/1248711
   Google Scholar
• Gagon, M. A. (2015). New drug pricing: Does it make any sense?. Prescrire International, 24(162), 192–195.
   PubMedGoogle Scholar
• Gault, K. (2016). Direct-to-consumer ads: Helpful or harmful?. Medical Economics, 93(3), 28.
   PubMedGoogle Scholar
• Giaccotto, C., Santerre, R. E., & Vernon, J. A. (2005). Drug prices and research and development investment behavior in the pharmaceutical industry. The Journal of Law & Economics, 48, 195–214. https://doi.org/10.1086/426882
   Web of Science ®Google Scholar
• Gleeson, D., & Menkes, D. B. (2018). Trade agreements and direct-to-consumer advertising of pharmaceuticals. International Journal of Health Policy and Management, 7(2), 98–100. https://doi.org/10.15171/ijhpm.2017.124
   PubMed Web of Science ®Google Scholar
• Good, M. C. (2020). Comparative and inducement appeals Rx by drug class. Health Marketing Quarterly (forthcoming).
   Google Scholar
• IMS Institute for Healthcare Informatics (2012, April). The use of medicines in the United States: Review of 2011. https://kaiserhealthnews.files.wordpress.com/2012/10/ihii_medicines_in_u.s_report_2011.pdf
   Google Scholar
• Jiang, P. (2018). Asking a doctor versus referring to the internet: a comparison study on consumers' reactions to DTC (direct-to-consumer) prescription drug advertising . Health Marketing Quarterly, 35(3), 209–226. https://doi.org/10.1080/07359683.2018.1514735
   PubMedGoogle Scholar
• Ju, I., & Park, J. S. (2013). When numbers count: Framing, subjective numeracy, and the effects of message quantification in direct-to-consumer prescription drug advertisements. Journal of Promotion Management, 19(4), 488–506. https://doi.org/10.1080/10496491.2013.817226
   Google Scholar
• Ju, I., & Park, J. S. (2018). Effects of risk disclosure prominence in direct-to-consumer advertising (DTCA) of prescription drugs: An integrative cognitive process model. Health Marketing Quarterly, 35(1), 32–46. https://doi.org/10.1080/07359683.2018.1434861
   PubMedGoogle Scholar
• Kassarjian, H. (1977). Content analysis in consumer research. Journal of Consumer Research, 4(1), 8–18. https://doi.org/10.1086/208674
   Web of Science ®Google Scholar
• Kiernicki, K., & Helme, D. W. (2017). Effects of image congruency on persuasiveness and recall in direct-to-consumer prescription drug advertising. Health Marketing Quarterly, 34(4), 284–301. https://doi.org/10.1080/07359683.2017.1375243
   PubMedGoogle Scholar
• Koinig, I., Diehl, S., & Mueller, B. (2018). Exploring antecedents of attitudes and skepticism towards pharmaceutical advertising and inter-attitudinal and inter-skepticism consistency on three levels: An international study. International Journal of Advertising, 37(5), 718–748. https://doi.org/10.1080/02650487.2018.1498653
   Web of Science ®Google Scholar
• Krippendorff, K. (1980). Content analysis: an introduction to its methodology. Sage.
   Google Scholar
• Lins Ferreira, V., Pereira da Veiga, C. R., Kudlawicz-Franco, C., Scalercio, P., Ramires, Y., Pontarolo, R., Carvalho, D. M. W., & da Veiga, C. P. (2017, July). Generic drugs in times of economic crisis: Are there changes in consumer purchase intention. Journal of Retailing and Consumer Services, 37, 1–7. https://doi.org/10.1016/j.jretconser.2017.02.008
   Web of Science ®Google Scholar
• Macias, W., & Lewis, L. (2003/2004). A content analysis of direct-to-consumer (DTC) prescription drug web sites. Journal of Advertising, 32(4), 43–56. https://doi.org/10.1080/00913367.2003.10639147
   Web of Science ®Google Scholar
• Mahoney, S. (2018, April 3). DTC Report 2018: Will more supersized campaigns follow Opdivo’s and Keytruda’s massive strikes?. Medical Marketing & Media, 32–39. https://www.mmm-online.com/home/channel/campaigns/dtc-report-2018-will-more-supersized-campaigns-follow-opdivos-and-keytrudas-massive-strikes/
   Google Scholar
• Martin, K. D., Josephson, B. W., Vadakkepatt, G. G., & Johnson, J. L. (2018). Political management, research and development, and advertising capital in the pharmaceutical industry: A good prognosis? Journal of Marketing, 82(3), 87–107. https://doi.org/10.1509%2Fjm.15.0297 https://doi.org/10.1509/jm.15.0297
   Web of Science ®Google Scholar
• Minemyer, P. (2018, November 28). Federal Watchdog’s ‘Arms Are Tied’ in Rethinking Drug Rebate Safe Harbors, Experts Say. FierceHealthcare, https://www.fiercehealthcare.com/payer/oig-s-arms-are-tied-its-plan-to-rethink-drug-rebate-safe-harbors-experts-say
   Google Scholar
• Minemyer, P. (2019, March 27). Policy to Bring down Drug Prices Can’t Begin and End with Rebates, Study Says. FierceHealthcare, https://www.fiercehealthcare.com/payer/policy-to-bring-down-drug-prices-can-t-begin-and-end-rebates-study-says
   Google Scholar
• Mukherji, J., & Mukherji, A. (2017). Attitudes toward pharmaceutical direct-to-consumer advertising: The role of culture. Journal of Competitiveness Studies, 25(2), 114–125.
   Google Scholar
• Muncy, J. A., Iyer, R., & Eastman, J. K. (2014). Medical advertising on demand: A content analysis of YouTube direct-to-consumer pharmaceutical advertisements. Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, 14(2-3), 145–153. https://doi.org/10.1177/1745790414564413
   Google Scholar
• O'Donoghue, A. C., Sullivan, H. W., Rupert, D. J., Fitts Willoughby, J., & Aikin, K. J. (2019). Actors in whitespace: Communicating risk information on pharmaceutical websites. Health Marketing Quarterly, 36(2), 152–167. https://doi.org/10.1080/07359683.2019.1575063
   PubMedGoogle Scholar
• Park, H., Rodgers, S., McElroy, J. A., & Everett, K. (2018). Sexual and gender minority's social media user characteristics: Examining preferred health information. Health Marketing Quarterly, 35(1), 1–17. https://doi.org/10.1080/07359683.2017.1310553
   PubMedGoogle Scholar
• Pavlou, F. (2011). Should we back DTC in Europe?. Pharmaceutical Technology Europe, 23(1), 6.
   Google Scholar
• Peters, R. (2017). 40 pharma's past serves as prologue to its future: The more pharma science and technology change, the more business and policy concerns stay the same. Pharmaceutical Technology, 41(7), 14–18.
   Google Scholar
• Preechavuthinant, S., Willis, W., & Coustasse, A. (2018). Trends and effects of pharmaceutical DTCA. International Journal of Pharmaceutical and Healthcare Marketing, 12(1), 61–70. https://doi.org/10.1108/IJPHM-04-2017-0019
   Web of Science ®Google Scholar
• Rifle, D., Lacy, S., & Fico, F. (1988). Analyzing media messages: using qualitative content analysis in research. Lawrence Erlbaum.
   Google Scholar
• Sar, S., & Rodriguez, L. (2019). The influence of mood and information processing strategies on recall, persuasion, and intention to get a flu vaccine. Health Marketing Quarterly, 36(1), 17–34. https://doi.org/10.1080/07359683.2019.1567002
   PubMedGoogle Scholar
• Slatko, J. (2016, February 10). Special feature - Agenda 2016: Bigger, better, faster, more. Pharmalive.com, http://www.pharmalive.com/special-feature-agenda-2016-bigger-better-faster-more/
   Google Scholar
• Stevens, E. M. (2018). What's so appealing? An examination of emotional appeals and viewer engagement in safe-sex PSAs and condom advertisements . Health Marketing Quarterly, 35(1), 18–31. https://doi.org/10.1080/07359683.2017.1375241
   PubMedGoogle Scholar
• Thorpe, K., Jain, S., & Joski, P. (2017). Prevalence and spending associated with patients who have a behavioral health disorder and other conditions. Health. Health Affairs (Project Hope), 36(1), 124–132. https://doi.org/10.1377/hlthaff.2016.0875
   PubMed Web of Science ®Google Scholar
• Tresca, A. J. (2019, June 12). Use Prescription Drug Coupons to Save Money. VeryWell Health.com, https://www.verywellhealth.com/use-prescription-drug-coupons-to-save-money-1941747
   Google Scholar
• Wechsler, J. (2018). Drug marketing and advertising under fire: FDA moves slowly in liberalizing off-label communications amid outrage over opioid promotion. Pharmaceutical Executive, 38(4), 8–9.
   Google Scholar
• Wechsler, J. (2019, June 18). Will Congress enact curbs on drug pricing? Pharmexec.com http://www.pharmexec.com/will-congress-enact-curbs-drug-pricing
   Google Scholar
• Wouters, O. J., Kanavos, P. G., & McKee, M. (2017). Comparing generic drug markets in Europe and the United States: prices, volumes, and spending. The Milbank Quarterly, 95(3), 554–601. https://doi.org/10.1111/1468-0009.12279
   PubMed Web of Science ®Google Scholar